Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.

Attarbaschi, A; Panzer-Grümayer, R; Mann, G; Möricke, A; König, M; Mecklenbräuker, A; Teigler-Schlegel, A; Bradtke, J; Harbott, J; Göhring, G; Stanulla, M; Schrappe, M; Zimmermann, M; Haas, O A

Attarbaschi, A; Panzer-Grümayer, R; Mann, G; Möricke, A; König, M; Mecklenbräuker, A; Teigler-Schlegel, A; Bradtke, J; Harbott, J; Göhring, G; Stanulla, M; Schrappe, M; Zimmermann, M; Haas, O A.

Afiliación

Attarbaschi A; Department of pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Panzer-Grümayer R; Children's Cancer Research Institute (CCRI), Vienna, Austria.
Mann G; Department of pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Möricke A; Department of Pediatric Hematology and Oncology, Children's University Hospital, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
König M; Children's Cancer Research Institute (CCRI), Vienna, Austria.
Mecklenbräuker A; Children's Cancer Research Institute (CCRI), Vienna, Austria.
Teigler-Schlegel A; Department of Pediatric Hematology and Oncology, Oncogenetic Laboratory, Justus-Liebig-University, Giessen, Germany.
Bradtke J; Institute of Pathology, Justus-Liebig-University, Giessen, Germany.
Harbott J; Department of Pediatric Hematology and Oncology, Oncogenetic Laboratory, Justus-Liebig-University, Giessen, Germany.
Göhring G; Institute of Cell and Molecular Pathology, Medical School of Hannover, Hannover, Germany.
Stanulla M; Department of Pediatric Hematology and Oncology, Medical School of Hannover, Hannover, Germany.
Schrappe M; Department of Pediatric Hematology and Oncology, Children's University Hospital, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Zimmermann M; Department of Pediatric Hematology and Oncology, Medical School of Hannover, Hannover, Germany.
Haas OA; Department of pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.

Klin Padiatr ; 226(6-7): 338-43, 2014 Nov.

Article en En | MEDLINE | ID: mdl-25431866

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Cromosomas Humanos Par 21/genética; Amplificación de Genes/genética; Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamiento farmacológico; Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética; Adolescente; Niño; Preescolar; Estudios de Cohortes; Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética; Supervivencia sin Enfermedad; Femenino; Estudios de Seguimiento; Humanos; Masculino; Neoplasia Residual/tratamiento farmacológico; Neoplasia Residual/genética; Neoplasia Residual/mortalidad; Leucemia-Linfoma Linfoblástico de Células Precursoras B/mortalidad; Proteínas Proto-Oncogénicas c-ets/genética; Recurrencia; Proteínas Represoras/genética; Proteína ETS de Variante de Translocación 6

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cromosomas Humanos Par 21 / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Protocolos de Quimioterapia Combinada Antineoplásica / Amplificación de Genes Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Klin Padiatr Año: 2014 Tipo del documento: Article País de afiliación: Austria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google